Director's Dealings

Cardiogeni PLC

29 August 2025

 

29 August 2025

Cardiogeni PLC

("Cardiogeni" or the "Company")

Director's Dealings

Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to advance novel heart failure medicines through human trials, announces that Ajan Reginald, Director of Cardiogeni has purchased a total of 12,001 ordinary shares of the Company, the details of which are set out in the notification below.

Following the purchase, Ajan Reginald's will hold 18,871,851 ordinary shares representing 22.11% of Cardiogeni's issued share capital.

The directors of Cardiogeni accept responsibility for this announcement.

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation.

For further information please contact:

Cardiogeni PLC
Dr Darrin M Disley OBE, Executive Chairman	Via First Sentinel
First Sentinel Corporate Finance Limited Corporate Adviser
Brian Stockbridge Gabrielle Cordeiro	[phone]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Ajan Reginald
2.	Reason for the Notification
a)	Position/status	Executive Chairman
b)	Initial notification / Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Cardiogeni PLC
b)	LEI	9845000F8F59ATZD8F92
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares
	ISIN	GB00BTBLFC12
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Date Price(s) Volume(s)  1.    29-08-2025 £0.20 10,001 2.    29-08-2025 £0.10 2000
d)	Aggregated information:  · Aggregated volume  · Price	£0.20 10,001 £0.10 2000
e)	Date of the transaction	29/08/2025
f)	Place of the Transaction	Aquis Exchange Growth Market (AQSE)

 

 

END